Muromonab

Prior to Initiation of Therapy

  • Should be administered under supervision of Experienced Personnel in Equipped Facility (for cardiopulmonary resuscitation)
  • Anaphylactic and anaphylactoid reactions may occur following administration of any dose or course.
  • Cardiotoxicity, CNS & Systemic Reactions: potentially life-threatening reactions including pulmonary edema, shock, cardiovascular collapse, cardiac/respiratory arrest, seizures, coma, cerebral edema, cerebral herniation, blindness and paralysis.
  • Cytokine Release Syndrome

Monitoring data

  • Fluid status carefully monitored at baseline and during therapy
  • Pretreatment with methylprednisolone to minimized Cytokine Release Syndrome

Package inserts

Additional information

Updated: January 2018